Safety and Efficacy Study of MAGE-A3 + AS-15 in Patients With Muscle-invasive Bladder Cancer After Cystectomy (MAGNOLIA)
A Randomized, Double Blind, Placebo Controlled Phase II Trial to Evaluate the Safety and Efficacy of recMAGE-A3 + AS15 ASCI in Patients With MAGE-A3 Positive Muscle Invasive Bladder Cancer After Cystectomy
Sponsor: European Association of Urology Research Foundation
Terminated
This trial was terminated. No reason was provided.
Other Urinary Bladder Neoplasms trials with similar outcome
This PHASE2 trial investigates Urinary Bladder Neoplasms and is currently terminated or withdrawn. European Association of Urology Research Foundation leads this study, which shows 10 recorded versions since 2011 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 5 earlier versions
-
Sep 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2019 — Sep 2020 [monthly]
Terminated PHASE2
-
Jun 2018 — Feb 2019 [monthly]
Terminated PHASE2
-
Jul 2017 — Jun 2018 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Jan 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Aug 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- European Association of Urology Research Foundation
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Aachen, Germany , Alcalá de Henares, Spain , Alcorcón, Spain , Amsterdam, Netherlands , Barcelona, Spain , Bari, Italy , Bordeaux, France , Bucharest, Romania , Cadiz, Spain and 33 more locations